

**UNITED STATES SECURITIES AND EXCHANGE
COMMISSION**

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104

Estimated average burden

hours per response: 0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

| | | | |
|--|---|--|---|
| 1. Name and Address of Reporting Person* <u>Kirk Sean</u> (Last) (First) (Middle) <u>400 PROFESSIONAL DRIVE,</u> <u>SUITE 400</u> (Street) <u>GAITHERSBURG MD 20879</u> (City) (State) (Zip) | 2. Date of Event Requiring Statement (Month/Day/Year) <u>03/05/2020</u> | 3. Issuer Name and Ticker or Trading Symbol <u>Emergent BioSolutions Inc. [EBS]</u> | |
| | | 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>EVP, Manufacturing & Tech Ops</u> | 5. If Amendment, Date of Original Filed (Month/Day/Year) <u>06/03/2019</u> 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person |

Table I - Non-Derivative Securities Beneficially Owned

| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
|---------------------------------|---|--|---|
| <u>Common Stock</u> | <u>12,180⁽¹⁾⁽²⁾</u> | <u>D</u> | |

**Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)**

| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
|--|--|-------------------|---|----------------------------|--|--|---|
| | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | | |
| <u>Employee Stock Options (Right to Buy)</u> | <u>(3)</u> | <u>03/31/2026</u> | <u>Common Stock</u> | <u>5,696⁽²⁾</u> | <u>50.52</u> | <u>D</u> | |

Explanation of Responses:

1. Consists of 2,933 shares, 1,424 unvested PSUs and 7,823 unvested RSUs granted from the Emergent Stock Incentive Plan. Each RSU and each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted net income as a percentage of GAAP revenue for the 2021 fiscal year, as certified by the Compensation Committee following the performance period. The RSUs vest in three equal installments annually on the day prior to the anniversary date of the grant.

2. The share amount reported herein has been amended to reflect a corrected share total from the form 3 filed on June 3, 2019.

3. Vests in three equal installments beginning on the day prior to the anniversary date of the grant.

Remarks:

/s/ S. Scott Lieberman,
Attorney-in-fact

03/06/2020

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.